Prescribing paradigm shift? Applying the 2019 european society of cardiology–led guidelines on diabetes, prediabetes, and cardiovascular disease to assess eligibility for sodium–glucose cotransporter 2 inhibitors or glucagon-like peptide 1 receptor agonists as first-line monotherapy (or add-on tometformin monotherapy) in type 2 diabetes in scotland

Thomas M. Caparrotta, Luke A.K. Blackbourn, Stuart J. McGurnaghan, John Chalmers, Robert Lindsay, Rory McCrimmon, John McKnight, Sarah Wild, John R. Petrie, Sam Philip, Paul M. McKeigue, David J. Webb, Naveed Sattar, Helen M. Colhoun, Scottish Diabetes Research Network–Epidemiology Group

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Prescribing paradigm shift? Applying the 2019 european society of cardiology–led guidelines on diabetes, prediabetes, and cardiovascular disease to assess eligibility for sodium–glucose cotransporter 2 inhibitors or glucagon-like peptide 1 receptor agonists as first-line monotherapy (or add-on tometformin monotherapy) in type 2 diabetes in scotland'. Together they form a unique fingerprint.

Medicine and Dentistry